MPOX-VAX Study

Red logo, text Mpox Vax

The Mpox-Vax: Vaccination to prevent Mpox Infection (Mpox-Vax) study is enrolling patients at a number of Irish hospitals. Mpox-Vax is a clinical trial examining the immune response to the mpox vaccination (MVA-BN vaccine) over time. It is led by Professor Eoin Feeney at University College Dublin and is funded by the Irish Health Research Board. 

This important study will look at the immune system's response to vaccination over time, how well this response works at preventing mpox infection, and whether infection happens without symptoms (“asymptomatic infection”). This will lead to important information on vaccine responses and durability.

The study is enrolling adults (>18 years old) who are eligible to receive the mpox vaccine or have received their first dose within the last 28 days. The study will collect and biobank samples, including blood samples and mouth/throat, rectal and/or vaginal swabs. All participants will receive routine sexual health care for one year as part of this study. Mpox-Vax is approved by the National Research Ethics Committee in Ireland and all participants provide written, informed consent. All participants will receive the standard vaccination as per national guidelines and receive routine sexual health care.​

If you are interested in partaking, or for further information, please contact: mpoxvax@ucd.ie.


Prof Eoin Feeney

St. Vincent’s University Hospital

Prof Patrick Mallon

St. Vincent’s University Hospital

Prof Mary Horgan

Mater Misericordiae University Hospital

Associate Prof. Aoife Cotter

Mater Misericordiae University Hospital

Dr Fiona Lyons

St. James's Hospital

Dr Eoghan de Barra

Beaumont Hospital, Dublin

Dr Corinna Sadlier

Cork University Hospital

Prof Catherine Fleming

University Hospital Galway

Dr Geraldine Moloney

University Hospital Galway

Dr Liem Binh Luong Nguyen

CIC Cochin Pasteur, Cochin Hospital, Paris